Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil

Brandileone, Maria-Cristina de C.; Zanella, Rosemeire Cobo; Almeida, Samanta Cristine Grassi; Cassiolato, Ana Paula; Lemos, Ana Paula Silva de; Salgado, Maristela Marques; Higa, Fábio Takenori; Minamisava, Ruth; Andrade, Ana Lúcia

doi:10.1016/j.vaccine.2019.07.043

Cited by 33 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study showed that the higher pneumococcal colonization density determined by quantitative molecular methods was strongly associated with microbiologically confirmed pneumococcal pneumonia (Baggett et al, 2017), thereby supporting the utility of more sensitive techniques for the detection of S. pneumoniae. Second, vaccine serotype coverage evaluations could have underestimated the protection provided by PCVs due to potential crossprotection between serotypes (Brandileone et al, 2019). Third, data regarding antimicrobial resistance by pneumococcal strains in different age groups are often limited, and thus it is important to collect more comprehensive data stratified by various age groups.…”

Section: Limitationsmentioning

confidence: 99%

Pneumococcal disease in Thailand

Gamil¹,

Chokephaibulkit

Phongsamart

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

This review examines the epidemiology of pneumococcal disease, serotype prevalence, antibiotic resistance, and national vaccination recommendations in Thailand. The incidence of invasive pneumococcal disease (IPD) and annualized hospitalization rates for pneumococcal bacteremia in Thailand were highest in children aged <5 years and the elderly. The most prevalent serotype is serotype 6B, which is included in both the 10-and 13-valent pneumococcal conjugate vaccines (PCV10 [also known as PHiD-CV] and PCV13, respectively) registered in Thailand. Other common serotypes are 14, 18C, 19F, and 23F (included in both PCVs) and 6A and 19A (only included in PCV13). PCV10/PHiD-CV and PCV13 should cover 48.8%-74% and 73.2%-92% of isolates among children aged 5 years, respectively, and 40.0%-47.9% and 58.3%-60.9% of isolates among adults aged !65 years. Only PCV13 is licensed for adults in Thailand. Pneumococcal isolates were most commonly resistant to erythromycin, cefuroxime, and penicillin. Despite their demonstrated cost effectiveness and efficacy in reducing nasopharyngeal carriage and IPD, PCVs are not included in the Thai national immunization program. The serotype-specific IPD incidence in Thailand suggests that PCVs will reduce the disease burden in all age groups, but particularly in children and older adults.

show abstract

Section: Limitationsmentioning

confidence: 99%

Pneumococcal disease in Thailand

Gamil¹,

Chokephaibulkit

Phongsamart

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…A total of 19 papers (out of 341 full-text journal publications identified from the online databases) [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] and 10 abstracts (out of 649 from relevant conference proceedings) [36][37][38][39][40][41][42][43][44][45] were included in the review (Figure 1). A summary of study characteristics is presented in Figure 2 and individual study details are provided in Table 2.…”

Section: Description Of Included Studiesmentioning

confidence: 99%

“…In terms of study designs, the most common was ecological database study (n = 13) 17,24,25,31-38,43,44 followed by surveillance-based (hospital-based or laboratory-based) (n = 9), [18][19][20]23,28,[40][41][42]45 cross-sectional (n = 5), 21,22,27,29,39 cohort (n = 1), 30 and case series (n = 1) ( Figure 2B).…”

Section: Description Of Included Studiesmentioning

confidence: 99%

“…The studies identified in this review assessed vaccine impact in specific age groups: <1-year-old (n = 3), 24,34,38 <2 years (n = 7), 21,22,25,30,31,33,36 1-4 year-olds (n = 4), 32,35,37,43 <6-yearsolds (n = 3), 17,29,44 and <16-years-olds (n = 3). 39,40,45 Nine studies reported data in individuals of all ages ( Figure 2C).…”

Section: Description Of Included Studiesmentioning

confidence: 99%

“…[18][19][20]23,[26][27][28]41,42 Most studies reported IPD as the outcome (n = 10), 19,20,23,[26][27][28]36,40,42,45 followed by pneumonia (n = 9), 17,24,25,32,35,37,38,43,44 community-acquired pneumonia (CAP) (n = 3), 33,34,39 pneumococcal meningitis (n = 3), 18,21,41 AOM/Otitis Media (OM) (n = 2) 30,31 and nasopharyngeal carriage (n = 3). 21,22,29 An overview of studies by outcome and target age group is provided in Figure 2D and Supplementary Figure 2.…”

Section: Description Of Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020

Guzmán-Holst¹,

Barros

Rubio

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In 2010, a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) was introduced in the Brazilian national immunization program; the 3 + 1 dose schedule was replaced by a 2 + 1 dose schedule in 2016. This systematic review presents the latest published evidence (2015-2020) on the impact after 10-year use of PHiD-CV in Brazil from a total of 29 publications. Overall, the PHiD-CV program had a positive impact on the morbidity and mortality associated with invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) in children <5 years-old. A reduction in the vaccine-type invasive disease was observed in all-ages; suggesting indirect protection unvaccinated older children and adults. The occurrence of non-vaccine type disease was evidenced in some studies. Higher vaccination coverage is required at national and state level for sustained population impact. Given the change in the vaccination schedule and the dynamics of pneumococcal disease epidemiology, continuous surveillance is warranted.

show abstract

Novel method for production and purification of untagged pneumococcal surface protein A from clade 1

da Costa Rodrigues,

Zorzete,

Miyaji

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Streptococcus pneumoniae can cause diseases with high mortality and morbidity. The licensed vaccines are based on capsular polysaccharides and induce antibodies with low cross reactivity, leading to restricted coverage of serotypes. For surpassing this limitation, new pneumococcal vaccines are needed for induction of broader protection. One important candidate is the pneumococcal surface protein A (PspA), which can be classified in 6 clades and 3 families. We have reported an efficient process for production and purification of untagged recombinant PspA from clade 4 (PspA4Pro). We now aim to obtain a highly pure recombinant PspA from clade 1 (PspA1) to be included, together with PspA4Pro, in a vaccine formulation to broaden response against pneumococci. The vector pET28a-pspA1 was constructed and used to transform Escherichia coli BL21(DE3) strain. One clone with high production of PspA1 was selected and adapted to high-density fermentation (HDF) medium. After biomass production in 6 L HDF using a bioreactor, the purification was defined after testing 3 protocols. During the batch bioreactor cultivation, plasmid stability remained above 90% and acetate formation was not detected. The final protein purification process included treatment with a cationic detergent after lysis, anion exchange chromatography, cryoprecipitation, cation exchange chromatography, and multimodal chromatography. The final purification process showed PspA1 purity of 93% with low endotoxin content and an overall recovery above 20%. The novel established process can be easily scaled-up and proved to be efficient to obtain a highly pure untagged PspA1 for inclusion in vaccine formulations. Key points • Purification strategy for recombinant PspA1 from Streptococcus pneumoniae • Downstream processing for untagged protein antigens, the case of PspA1 • Purification strategy for PspA variants relies on buried amino acids in their sequences

show abstract

Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil

Cited by 33 publications

References 38 publications

Pneumococcal disease in Thailand

Pneumococcal disease in Thailand

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020

Novel method for production and purification of untagged pneumococcal surface protein A from clade 1

Contact Info

Product

Resources

About